Medios achieves double-digit growth in 2023 - Positive outlook for 2024

EQS-News: Medios AG / Key word(s): Annual Results
Medios achieves double-digit growth in 2023 - Positive outlook for 2024

27.03.2024 / 07:54 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Press release

Medios achieves double-digit growth in 2023 - Positive outlook for 2024

Berlin, March 27, 2024 - Medios AG ("Medios"), the leading provider of
specialty pharma solutions in Germany, once again grew strongly in the 2023
financial year. From January to December 2023, consolidated revenue
increased by 10.8% to around EUR1.8 billion (previous year: EUR1.6 billion),
thus meeting the latest forecast. EBITDA pre1 rose by 10.3% to around EUR60.5
million (previous year: EUR54.9 million), exceeding the most recent forecast
of around EUR60 million. The EBITDA pre1 margin thus remained at the previous
year's level of 3.4%.

Highlights:

  * Increase in consolidated revenue in 2023 by approx. 11% to around EUR1.8
    billion; EBITDA pre1 2023 increases by 10.3% to EUR60.5 million with
    stable EBITDA pre1 margin of 3.4%.

  * Closing of the acquisition of the Dutch market leader for pharmaceutical
    compounding services Ceban expected in the second quarter of 2024.

* Guidance 2024: Significant increase in revenue and margin: revenue
between EUR1.9 billion and EUR2.1 billion; EBITDA pre1 between EUR82 million and EUR91 million with a margin of around 4.3%.

  * Medium-term outlook for the 2025 financial year: revenue of around EUR2.15
    billion and EBITDA pre1 of around EUR110 million, which corresponds to a
    margin of around 5.1%.

Matthias Gärtner, Chief Executive Officer (CEO) of Medios AG: "Despite
challenging conditions in the 2023 financial year, we continued to
consistently implement our growth strategy and once again achieved our
ambitious forecast in the 2023 financial year. With the recent acquisition
of the Dutch compounding manufacturer and market leader Ceban, we are
implementing a significant strategic growth measure. This is just the
beginning: We want to expand into other European countries and enter the
market for personalized medicine."

Growth in both operating segments

The Pharmaceutical Supply segment generated external revenue of EUR1,558
million in the 2023 financial year (previous year: EUR1,390 million), which
corresponds to an increase of 12.1% compared to the previous year. EBITDA
pre1 increased by 22.8% to EUR46.7 million (previous year: EUR 38.0 million).

The Patient-Specific Therapies segment generated external revenue of EUR226.0
million in the same period (previous year: EUR220.0 million), up 2.7% on the
previous year. EBITDA pre1 decreased by around 8.0% year on year to around
EUR21.8 million (previous year: EUR23.7 million), which is mainly due to a
decline in gross profit as a result of regulatory price reductions
(auxiliary tax reductions) for some active ingredients since September 2022.

Positive outlook for the 2024 and 2025 financial years

The company expects revenue of EUR1.9 billion to EUR2.1 billion and EBITDA pre1
of EUR82 million to EUR91 million for 2024. This expectation is based in
particular on the assumption that Ceban will be fully consolidated from May
1, 2024.

Through the realization of synergies and further organic growth Medios
expects revenue to increase to around EUR2.15 billion and EBITDA pre1 to
around EUR110 million in the 2025 financial year, which corresponds to a
significant increase in the EBITDA pre1 margin to 5.1%.

    Key figures (IFRS)
    in EUR million                             2023       2022     in %
    Revenue                               1,784.7    1,610.8      10.8
    Pharmaceutical Supply                 1,558.1    1,390.3      12.1
    Patient-Specific Therapies              226.0      220.0       2.7
    Services                                  0.6        0.5      14.1
    EBITDA pre1                              60.5       54.9      10.3
    Pharmaceutical Supply                    46.7       38.0      22.8
    Patient-Specific Therapies               21.8       23.7      -7.8
    Services                                 -8.0       -6.8      17.4
    Cashflow from operating activities       16.4       37.1     -55.8

Medios AG's Annual Report 2023 is available for download on the Investor
Relations website.

1 EBITDA is defined as consolidated earnings before interest, taxes,
depreciation and amortization. EBITDA pre is adjusted for special charges
for stock options and expenses for M&A activities as well as for one-off
performance-related payments for the acquisition of production volumes and,
from 2024, for expenses for the introduction of an ERP system.

-------------------

About Medios AG

Medios AG is the leading provider of Specialty Pharma Solutions in Germany.
As a competence partner and expert, Medios covers all relevant aspects of
the supply chain in this field: from pharmaceutical supply to the
manufacture of patient-specific therapies including blistering. The focus is
on optimal patient care via specialized pharmacies.

Medios AG is Germany's first listed specialty pharmaceutical company. The
shares (ISIN: DE000A1MMCC8) are listed on the Regulated Market of the
Frankfurt Stock Exchange (Prime Standard).

www.medios.ag

Contact

Claudia Nickolaus
Head of Investor & Public Relations, ESG Communications
Medios AG
Heidestraße 9 | 10557 Berlin
T +49 30 232 566 800
c.nickolaus@medios.ag

www.medios.ag

Disclaimer

This communication contains forward-looking statements that are subject to
certain risks and uncertainties. Future results could differ materially from
those currently anticipated as a result of various risk factors and
uncertainties, including, but not limited to, changes in business, economic
and competitive conditions, foreign exchange rate fluctuations,
uncertainties in litigation or investigative proceedings and the
availability of financing.


---------------------------------------------------------------------------

27.03.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Medios AG
                   Heidestraße 9
                   10557 Berlin
                   Germany
   Phone:          +49 30 232 566 - 800
   Fax:            +49 30 232 566 - 801
   E-mail:         ir@medios.ag
   Internet:       www.medios.ag
   ISIN:           DE000A1MMCC8
   WKN:            A1MMCC
   Listed:         Regulated Market in Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
   EQS News ID:    1868135

End of News EQS News Service
---------------------------------------------------------------------------

1868135 27.03.2024 CET/CEST